Clinical trial
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That…
NCT00348699 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00348699 |
|---|---|
| Title | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery |
| Official title | A Phase I Study and Pharmacological Trial of Once Weekly Aminoflavone Prodrug (AFP464) Administered 3 Out of Every 4 Weeks in Solid Tumor Patients |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Renal Cell Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor and 1 more |
| Intervention type | Drug, Other |
| Interventions | AFP464, pharmacological study, laboratory biomarker analysis |
| Enrollment | 68 |
| Start date | Jul 1, 2006 |
| Primary completion | Jan 1, 2013 |
| First posted | Jul 6, 2006 |
| Last update posted | Feb 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: